Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC). This is an ASCO Meeting ...

Type 1 dendritic cells are key to initiate and maintain anti-tumoral T-cell responses in diverse tumour tissues. Our lab focuses on tissue-specific properties of cDC1 in lung tumours, focusing on the ...

KRAS driver mutations are found in greater than ... alteration-specific therapeutics to address high-value and validated oncogenic drivers. Our pipeline includes two Phase 1 therapies in ...

Genes involved in the regulation of cell division, movement and signalling for example can function as oncogenes under specific conditions. Although enhancing the GTPase activity of KRAS is an ...

Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data ...

To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on ...

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data reado ...

This patent aims to develop small-molecule inhibitors targeting mutant KRAS proteins to block oncogenic signaling. The patent describes compounds designed to selectively inhibit KRAS mutations by ...

Every day, billions of cells in your body divide, helping to replace old and injured cells with new ones. And each time this ...

Researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a potential therapeutic target in cancer.